Newsroom

Sorted by: Latest

-

Fairholme Funds, Inc. December 2025 Dividend Distributions

MIAMI--(BUSINESS WIRE)--FAIRHOLME FUNDS, INC. THE FAIRHOLME FUND (FAIRX) On December 12, 2025, the Fairholme Fund (NASDAQ: FAIRX) distributed an Ordinary Income dividend of $0.22209 per share to shareholders of record as of December 11, 2025. The Fairholme Fund’s Net Asset Value (“NAV”) was reduced by the total amount of the distribution. The Record Date, Ex-Dividend Date, Payable Date, and Cents-Per-Share are as follows: Distribution Type Record Date Ex-Dividend Date Payable Date Cents-Per-Sha...
-

Halliburton Fourth Quarter 2025 Earnings Conference Call

HOUSTON--(BUSINESS WIRE)--Halliburton Company (NYSE: HAL) will host a conference call on Wednesday, January 21, 2026, to discuss its fourth quarter 2025 financial results. The call will begin at 8:00 a.m. CT (9:00 a.m. ET). The Company will issue a press release regarding the fourth quarter 2025 earnings prior to the conference call. The press release will be posted on the Halliburton website at www.halliburton.com. Please visit the Halliburton website to listen to the call via live webcast. A...
-

Securities Fraud Investigation Into Fermi Inc. (FRMI) Announced – Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Fermi Inc. (“Fermi” or the “Company”) (NASDAQ: FRMI) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON FERMI (FRMI), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On October 1, 2025, Fermi began...
-

Granite Real Estate Investment Trust Announces Final Day of Trading on the NYSE

TORONTO--(BUSINESS WIRE)--Granite Real Estate Investment Trust (“Granite” or the “Trust”) (TSX: GRT.UN / NYSE: GRP.U) announced today that the last day of trading for Granite’s trust units ("Units") on the New York Stock Exchange ("NYSE") is expected to be December 31, 2025. Granite has filed an application for its Units to be quoted on the OTCQX platform, operated by OTC Markets Group Inc., and expects trading to begin on or about January 2, 2026. Unitholders will not be required to exchange t...
-

OFS Credit Company Provides November 2025 Net Asset Value Update

CHICAGO--(BUSINESS WIRE)--OFS Credit Company, Inc. (Nasdaq: OCCI) (“OFS Credit”, the “Company”, “we”, “us” or “our”), an investment company that primarily invests in collateralized loan obligation (“CLO”) equity and debt securities, today announced the following net asset value (“NAV”) estimate at November 30, 2025. Management’s unaudited estimate of the range of our NAV per share of our common stock at November 30, 2025 is between $5.01 and $5.11. This estimate is not a comprehensive statement...
-

Non-Opioid Therapeutics Market Insights, Shares and Growth Outlook 2025-2032: Rising Integration of Non-Opioid Options in Multimodal Pain Management Protocols - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Non-Opioid Therapeutics Market - Global Forecast 2025-2032" has been added to ResearchAndMarkets.com's offering. This market research report focuses on the evolving landscape of the Non-Opioid Therapeutics Market. This sector has grown from USD 40.77 billion in 2024 to USD 43.78 billion in 2025, with projections suggesting a CAGR of 7.68% leading to a valuation of USD 73.72 billion by 2032. Non-opioid therapeutics have become critical in modern pain management, add...
-

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of NUZOLVENCE was part of a private, not-for-profit collaboration...
-

Bausch + Lomb Announces Refinancing of Outstanding Term B Loans

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000 tranche (the “Replacement Term Loans”) of new term B loans, the proceeds of which will be used to refinance all of its outstanding term B loans due 2031 (the “Third Amendment Term Loans”) and its outstanding term B loans due 2028 (the “First I...
-

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, res...
-

Samenvatting: Gloednieuwe IP PRAGMATA van Capcom wordt gelanceerd op 24 april 2026!

OSAKA, Japan--(BUSINESS WIRE)--Capcom Co., Ltd. (TOKYO:9697) heeft vandaag aangekondigd dat de sciencefiction-actie-avonturengame PRAGMATA, een volledig nieuwe IP, op 24 april 2026 zal worden uitgebracht. PRAGMATA is een nieuw type sciencefiction-actie-avonturengame die puzzel- en actie-elementen combineert. In de game, die zich afspeelt op de maan in een nabije toekomst, werken de in een ruimtepak gehulde Hugh en het androïde meisje Diana samen terwijl ze vechten om terug te keren naar de aard...